Population Bioequivalence (PBE) analysis for in-vitro studies [Regulatives / Guidelines]

posted by ElMaestro  – Denmark, 2019-05-23 08:50 (859 d 18:08 ago) – Posting: # 20296
Views: 1,997

Hello kotu,

» Population Bioequivalence (PBE) analysis is required for in-vitro studies as per FDA guidance for few products like Iron Sucrose Injection, Ciclosporine Ophthalmic Emulsion, Azelastine Nasal spray etc.
»
» For performing PBE analysis there are two statistical methods
» 1. One-sided PBE
» 2. Traditional PBE

I am not sure what is meant here, can you elaborate?
How did you see two options for PBE apart from vague hints that applicants may propose their own methods etc?

PBE is well-defined but largely abandoned for in vivo crossover studies. For in vitro trials, your situation, a variant of PBE was introduced in the Budenoside guidance and it is often your method of choice.

» If the study is meeting criteria as per one-sided PBE analysis & not meeting the criteria as per the traditional PBE analysis, whether that study will be accepted by regulatory?

Rhetorically, you are testing the question using the method you specified in your protocol prior to conducting the experiment.

Pass or fail!
ElMaestro

Complete thread:

Activity
 Admin contact
21,704 posts in 4,538 threads, 1,541 registered users;
online 4 (0 registered, 4 guests [including 3 identified bots]).
Forum time: Wednesday 02:59 CEST (Europe/Vienna)

It has yet to be proven
that intelligence has any survival value.    Arthur C. Clarke

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5